A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.

Summary

1. Primary Objective: To evaluate the dose-response relationship of tarafenacin on efficacy. 2. Secondary Objectives: * To compare 12 weeks' efficacy of different doses of tarafenacin to that of placebo in patients suffering from Overactive Bladder. . * To compare the tolerability of different doses of tarafenacin to that of placebo in patients suffering from Overactive Bladder. .

Timeline

Start

2011-09

Primary completion

2012-08

Completion

2012-11

Drugs

Indications